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Abstract: 
In the pharmaceutical industry, the production of solid dispersions is generally 
accepted as a method to enhance the oral bioavailability of drugs with low aqueous 
solubility. Two processes commonly employed to create solid dispersions are examined 
in this research.  The first technique dissolves the drug and carrier in a common organic 
solvent and is followed by a solvent-removal operation.  The second method processes 
both the drug and polymer in a high-pressure mixer with supercritical carbon dioxide.  
This method is intended to simulate the temperature and pressure conditions of carbon 
dioxide-assisted hot-melt extrusion.  
Organic solvent-based solid dispersion formulation techniques are accompanied 
by environmental challenges, due to disposal of the solvent, and are generally more 
costly than extrusion applications.  However, the application of hot-melt extrusion 
technologies has been limited due to the temperature-sensitive nature of the drugs and the 
high processing temperatures associated with the extrusion process.  The inclusion of 
supercritical fluids, such as carbon dioxide, in the polymer-melt extrusion method has 
proved to significantly lower processing temperatures, thereby extending the technique to 
thermo-labile compounds.   
Yet the properties of solid dispersions created in this manner have traditionally 
been unpredictable.  This study systematically analyzes the properties of solid dispersions 
formulated by supercritical carbon dioxide-assisted techniques and compares these 
characteristics to those of solid dispersions created using the organic-solvent method. 
 Composite samples of 4-aminosalicylic acid, a sample drug compound, and 
eudragit E100, an acrylate block copolymer, were formulated using both the organic 
 
solvent method and a carbon dioxide-assisted high-pressure mixing process.  Due to the 
costly nature of the drug and polymer, the high-pressure mixer approach was employed to 
simulate extruder conditions in a batch operation and characterize the suitability of 
materials for extrusion. Drug-polymer composites were made using the organic-solvent 
method.  The processing temperature of these samples was kept low so that it could be 
used as a standard to examine the effects of heat.  In the high-pressure mixer technique, 
the same ratio of drug-polymer was processed with supercritical carbon dioxide.  Process 
temperatures and carbon dioxide pressures were varied.   
Samples from each method were analyzed using differential scanning calorimetry 
(DSC) to measure thermal properties and Fourier-transform infrared (FTIR) spectroscopy 
to examine drug-polymer interactions and dispersion properties.  High-pressure 
differential scanning calorimetry (HPDSC) was further utilized to examine the 
morphology of the composites while in equilibrium with carbon dioxide.  Results of this 
study examine the use of a high-pressure mixer to simulate extrusion conditions and 
distinguish between composites made by organic solvent and supercritical carbon 
dioxide-assisted processes.    
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I.  INTRODUCTION 
1.1  Pharmaceutical Composite Formulation Techniques 
 Pharmaceutical composites are generally comprised of active drug compounds 
and biodegradable polymer carriers.  The inclusion of polymer carriers is essential to 
control both the rate of drug delivery and the formation of solid dispersions.  The 
production of solid dispersions is commonly acknowledged as a method to enhance the 
aqueous solubility, thereby increasing the oral bioavailability, of drugs with low 
solubility in water.  The production methods used to create dispersions can generally be 
divided into two categories.   
The first technique dissolves the drug and carrier in a common organic solvent 
and is followed by a solvent-removal operation, such as evaporation.  This evaporation 
can be accomplished, for example, by spray-drying, wherein the solution is dispersed into 
fine droplets.  By increasing the surface area of the solution, the solvent is rapidly 
evaporated, and the resulting composite particles are collected.  The second method melts 
both the carrier and drug, and then cools the melt to form a solid dispersion.  In fact, 
some methods allow for the distribution of the solid drug in a molten carrier to minimize 
processing temperatures and reduce drug degradation. In recent years, hot-melt extrusion 
has become an attractive alternative to traditional solvent-based methods (Breitenbach, 
2002).  Extrusion offers a solvent-free process to produce solid dispersions.  In addition 
to concerns regarding residual solvent, solvent-based solid dispersion formulation 
techniques are accompanied by environmental challenges due to disposal of the organic 
solvent and are generally more costly than extrusion applications; therefore, it seems that 
the extrusion technique is preferable (Forster, 2001).     
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1.2  Expanding the Applicability of Extrusion in Pharmaceutical Applications 
 Although melt-extrusion methods can be applied to disperse drugs in a polymeric 
matrix down to the molecular level (Breitenbach, 2002), the number of extrusion-based 
solid dispersion applications in the pharmaceutical industry is limited.  The long 
residence time and high temperature needed for processing leads to drug degradation; 
therefore, the technology has only been applied to polymers that exhibit low glass 
transition temperatures (Tg).  The applicability of a material for the extrusion process is 
dictated by its Tg, which is the transition between regions of high and low molecular 
mobility, and the sensitivity of the polymeric matrix or drug toward heat and shear force. 
 For thermo-labile compounds, a plasticizer may be added to the composite.  The 
small molecules traditionally used as plasticizers increase polymer chain mobility by 
weakening the polymer-polymer interactions, thus reducing viscosity and Tg, and 
lowering minimum process temperatures (Verreck, 2003).  However, this added material 
increases the final weight of the product, which is a distinct disadvantage in 
pharmaceutical applications.  Research has shown that drug compounds can act as 
plasticizers when processed with polymers.  For example, the common drug compound 
ibuprofen has proved to function as a non-traditional plasticizer in hot-melt extrusion 
applications.  Composites of 60/40 wt % ibuprofen/ethyl cellulose have been extruded at 
temperatures as low as 60oC, although the Tg of ethyl cellulose exceeds 130oC 
(DeBranbander, 2002).   
Supercritical fluids (SCFs) are at such temperature and pressure conditions that 
they exhibit gas-like transport properties but also demonstrate liquid-like solvent 
capacities and densities.  Consequently, an SCF can act as a temporary plasticizer for the 
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polymeric carrier and as a solvent for the drug compound, thereby assisting in the 
formation of solid dispersions.  Moreover, when the material exits the extruder and the 
pressure is released, the SCF expands to its gaseous form and escapes from the polymer 
to create a foam.  This foam contains no plasticizer or solvent residue and is easily milled 
into powder for feeding into a pill press, thereby reducing the thermal and mechanical 
stress on the product relative to conventional solvent-based methods.  Thus, the 
application of SCFs to assist the extrusion process has expanded the technique to thermo-
labile compounds.   
 
1.3  Supercritical Carbon Dioxide 
Supercritical carbon dioxide (SC-CO2) is commonly used in SCF applications 
because of its relatively low critical temperature (Tc = 31.05oC).  Additionally, carbon 
dioxide is non-flammable, inert, inexpensive, environmentally benign relative to other 
solvents, and exhibits antibacterial properties.  Furthermore, the compound is not yet 
regulated by the Food and Drug Administration, making it particularly suitable for 
pharmaceutical use.   
 While this area of research remains somewhat novel, new methods to create and 
characterize polymer-drug composites using SCF-assisted extrusion are of particular 
interest to pharmaceutical research groups.  Previous research in the laboratory of Dr. 
David Tomasko studied the viscosity reduction and glass-transition temperature 
depression of various pharmaceutical polymers under SC-CO2.  For example, DSC trials 
conducted by Hongbo Li examine the contrasting effects of pressurized nitrogen and 
carbon dioxide in equilibrium with polystyrene.  Over a pressure range of 1 to 65 bar, 
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carbon dioxide decreases the glass-transition temperature 15 times as much as nitrogen.  
At 65 bar, the Tg of polystyrene is approximately 40oC below the Tg at ambient pressure. 
In addition, polymer-drug composites have been processed using traditional and tandem 
carbon dioxide-assisted extrusion processes, and the results have been characterized 
using DSC and fluorescence microscopy.   
This research has been performed in conjunction with the Janssen Research 
Foundation in Belgium.  There, researchers have used carbon dioxide-assisted extrusion 
to study dissolution rates and morphological effects of carbon dioxide on drug-polymer 
composites.  Thermogravimetric analysis (TGA) has been utilized to determine upper 
process temperature limits for various polymers and drug compounds, and high pressure 
liquid chromatography (HPLC) has been used to examine drug degradation.  
 In spite of the simplicity of extrusion as a manufacturing method to create solid 
dispersions, the number of marketed products arising from this approach has been 
disappointing (Craig, 2002).  The lack of predictability of solid-dispersion behavior can 
be attributed to a poor understanding of its properties.  In solid dispersions, the physical 
state of the drug is often changed from crystalline to amorphous.  The absence of the 
crystalline lattice leads to dramatically improved dissolution properties, which is 
beneficial for drugs with low solubility (Six, 2002).  However, in the majority of cases, it 
is unclear whether the drug is present as a molecular, a crystalline particulate, or an 
amorphous particulate dispersion (Craig, 2002).  Finding a method to systematically 
examine the properties of solid dispersions produced by SC-CO2 assisted extrusion, and 
the effects of SC-CO2 and drug concentration on these properties, is crucial for the 
application of this technology in the pharmaceutical industry.   
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1.4  Purpose 
 The aim of this research was to characterize the physical properties of solid 
dispersions resulting from SC-CO2-assisted mixing techniques, and to differentiate these 
products from those created using standard organic-solvent methods.  Significant 
considerations included the verification of sufficient drug dispersion within the polymer 
carrier and the prevention of drug degradation.  The primary objective was to obtain 
representative samples from both the organic-solvent and SC-CO2-assisted melt 
formulation techniques, the latter while varying system parameters.  Resulting samples 
were then characterized using DSC and FT-IR spectroscopy.  Information on composite 
samples was collected using a batch SC-CO2-assisted melt operation with the goal of 
determining the suitability of a material for melt extrusion.  The results of this research 
should help to provide fundamentals for the widespread application of extrusion 





II.  EXPERIMENTAL 
2.1  Materials 
 The materials used in the composite formulations consisted of a model drug 
compound and a model pharmaceutical polymer.  Due to the costly nature of authentic 
drug compounds and pharmaceutical polymers, model materials were utilized in this 
research.  The model drug compound, 4-aminosalicylic acid (4-ASA), is a specific 
bacteriostatic agent applied in the treatment of pulmonary tuberculosis (Verreck, 2005).  
The 4-ASA (99% purity, Batch #11111TB) was supplied by Aldrich®.  The drug, a 
thermally-labile active substance, melts at 135oC with significant decomposition 
occurring near 120oC (Verreck, 2005).  The chemical structure of 4-ASA is shown below 
in Figure 1. 
                                                   
Figure 1:  Chemical Structure of 4-aminosalicylic acid 
  
The model pharmaceutical polymer, Eudragit E100, is an acrylate block 
copolymer composed of 2-dimethyl aminoethyl methacrylate, methyl methacrylate, and 
n-butyl methacrylate in a molecular ratio of 2:1:1, respectively.  Eudragit E100 (Lot 
#8320401074) was obtained from Rhom Pharma Polymers® in the form of 3 mm 
diameter pellets.  The model pharmaceutical polymer experiences a glass transition in the 
temperature region of 50oC.  Significant thermal decomposition of the polymer occurs at 







and numerous organic solvents such as isopropanol, ethanol, and acetone.  The chemical 
structure of Eudragit E100 is depicted in Figure 2. 
                                  
Figure 2:  Chemical Structure of Eudragit E100 
The carbon dioxide used in both the CO2-assisted high-pressure mixing technique, 
as well as the high-pressure DSC analyses, was 3.0 grade (> 99.9% purity) supplied by 
Praxair.  Acetone, used as the solvent in the organic solvent formulation method, was 
obtained from Mallinckrodt Chemicals (> 99.7% purity, Lot #A46B34). 
 
2.2  Organic Solvent Method 
In the organic-solvent formulation method, a 10 wt% 4-ASA in Eudragit E100 
solution was made.  Based on mutual solubility of the drug and polymer, as well as its 
high volatility, acetone was chosen as the solvent.  A minimal amount of acetone was 
employed such that the drug and carrier were completely dissolved after sufficient 
agitation.  The solvent was then evaporated using a Fisher Isotemp Vacuum Oven, Model 
282.  The vacuum oven temperature was set at 35oC, which is below the Tg of Eudragit 
E100 and well under the decomposition temperatures of both the drug and polymer.  By 
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maintaining low temperatures throughout the formulation of these composites, it was 
assumed that the resulting samples could serve as standards against which the effects of 
heat could be compared.  The pressure in the oven was decreased to approximately 0.1 in. 
of Hg using a Welch Duo-seal Vacuum Pump with a 1 horsepower motor manufactured 
by Franklin Electric.  The organic-solvent method composites were held under these 
conditions for a period of two days.  The samples were then ground with a mortar and 
pestle, and one of the two composites created in this manner was again placed in the 
vacuum oven under the aforementioned conditions to ensure adequate solvent removal.   
 
2.3  SC-CO2-Assisted High-Pressure Mixing Method 
The high-pressure mixing method was used to simulate the temperature and 
pressure conditions in CO2-assisted hot-melt extrusion applications.  These batch 
operations used dramatically less material than a continuous extrusion process while 
creating a qualitatively similar foam product. 
In the high-pressure mixer technique, the same ratio of drug:polymer (10:90 wt%) 
was melted in a Pressure Products Industries, Inc. FC Series Reaction Vessel (rated 
6000psi at 650oF).  A calibration curve for the temperature inside the reaction vessel was 
constructed prior to composite formulation.  The mixture of drug and polymer was heated 
for two hours at the desired process temperature, which was varied from 80-120oC.  
Carbon dioxide was then added to the reaction vessel via an ISCO Model 500D Syringe 
Pump.  Control of the pressure was established using an ISCO Series D Pump controller.  
The reaction vessel was given sufficient time to equilibrate with carbon dioxide at the 
desired pressure, either 1500 or 2000psi.  Therefore, once the carbon dioxide reached the 
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reaction vessel, the compound was in its supercritical state.  The Dynamag Magnetic 
Drive mixing rotor was then set to 250 rpm using a SP500 Rotor Control and activated, 
and the sample was processed at the set conditions for four hours.  Afterward, the 
reaction vessel was given time to cool, the pressure was released, and the resulting 
samples were crushed using a mortar and pestle.  A photograph of the SC-CO2-assisted 
high-pressure mixing apparatus is shown in Figure 3.    
              
Figure 3:  Photograph of high-pressure mixing apparatus (mixer left, syringe pump right) 
Initially, samples processed at the upper temperature ranges became significantly 
discolored.  A high-pressure mixer sample containing only polymer was then processed 
at 120oC and 1500psi.  Because no discoloration was observed in the pure polymer 
sample, it was confirmed that the discoloration was attributed to drug degradation caused 
by oxidation during the melting step.  Therefore, a carbon-dioxide purging step prior to 




2.4  Differential Scanning Calorimetry   
 Representative composite samples were obtained for each set of system 
parameters.  Differential Scanning Calorimetry was performed to evaluate the thermal 
properties of the pure drug and polymer, as well as the characteristics of both the organic-
solvent and high-pressure mixer composite samples.  Eudragit E100 is an amorphous 
copolymer and thus possesses a glass transition.  DSC analyses plot the heat flow as a 
function of temperature.  If the composite sample is in an amorphous state, it will 
undergo a glass transition corresponding to a decrease in heat capacity.  A downward 
shift will be observed in the plot, and this endothermic transition is used to determine the 
composite’s Tg.  Frequently, the glass transition is accompanied by an enthalpy 
relaxation, which is seen as an endothermic signal superimposed on the glass transition.  
In its pure state, 4-ASA is a crystalline drug and thus exhibits a melting peak.  If the drug 
is present in its crystalline form, an inverse peak in the plot corresponding to the melting 
point of the crystals will be observed.  Figure 4 presents a generic DSC plot with 
common features.  The effects of processing temperatures and CO2 pressures on Tg 
depression and dispersion characterization are studied. 
 
Figure 4:  Sample DSC Scan (State of composite will dictate observed trends) 
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The analyses were performed using a TA Instruments DSC 2920 Differential 
Scanning Calorimeter.  Nitrogen was used as a purge gas at a rate of 50 mL/min.  The 
DSC cell was calibrated using indium as a reference material.  The samples were 
analyzed in hermetically sealed TA Instruments pans.  Approximately 10 mg of sample 
was heated from 25oC to 190oC, which encompassed the entire range of the glass-
transition and melting peaks, with a heating rate of 10oC/min.  The glass-transition 
temperature was determined at the inflection point as half the height of the shift in the 
heat-flow signal.  The melting temperature was measured by determining the minimum 
point of the inverse peak, and the enthalpy of melting was calculated by integrating the 
area of the inverse peak.  The samples were analyzed at least in duplicate, depending on 
the precision of the results.  Figure 5 is a photograph of the differential scanning 
calorimeter apparatus employed in this research. 
          
Figure 5:  Photograph of Differential Scanning Calorimeter 
Additionally, samples were analyzed using high-pressure differential scanning 
calorimetry to determine the effects of carbon dioxide as a plasticizer on the composites.  
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A TA Instruments high-pressure DSC cell was added to the regular DSC setup, and 
pressurized carbon dioxide was injected using an ISCO Model 500D Syringe Pump. 
 
2.5  Fourier Transform Infrared Spectroscopy  
 Fourier-transform infrared (FTIR) spectroscopy was performed on each of the 
samples to determine the structure of the organic compounds and to identify the presence 
of specific functional groups within a sample.  Furthermore, drug-polymer 
interactions were examined using the resulting spectra.  In this case, the infrared spectra 
were obtained using a scale of wave numbers (cm-1).  The benefit to using wave numbers 
is that the units are directly proportional to energy, so the higher the wave number, the 
higher the energy of the infrared radiation. 
 Spectra are obtained by passing infrared radiation through a sample and 
determining what fraction of incident radiation is absorbed at a particular energy.  The 
energy of a peak in the spectrum corresponds to the frequency of vibration of part of the 
sample compound.  For a molecule to have IR absorptions, an electric dipole moment of 
the molecule must change, which corresponds to an excitation of a vibrational energy 
state of a functional group.  A single molecule can have many distinct vibrational states.  
 The analyses were performed using a Thermo Nicolet Nexus 470 FTIR ESP.  3-5 
mg of composite sample was added to approximately 100 mg of KBr (s).  The mixture 
was then ground to a fine powder using a mortar and pestle, and transparent discs were 
formed using a pellet press.  The discs were then placed in the FTIR spectroscopy 
apparatus, and spectra were collected.  The range of the collected spectra was 4000-400 








III.  RESULTS AND DISCUSSION 
3.1  Qualitative Results of Formulation Methods 
 Qualitatively, the product of the organic solvent method was a dark orange 
translucent solid of almost crystalline density and appearance.  In contrast, the resultant 
sample from the high-pressure mixer was porous foam of a light brown shade, similar in 
color to a combination of the pure drug and polymer.  Figure 7 illustrates the different 
appearances of the product resulting from each method.   
  
Figure 7: Photo of Organic Solvent and High Pressure Mixer (80oC, 1500psi) Products 
Because the process temperatures during the organic solvent formulations were 
maintained well under the decomposition temperatures of both the drug and polymer, it 
was assumed that the resulting samples would serve as standards against which the 
effects of heat could be compared.  However the discoloration of the sample indicates 
that product degradation may have occurred.  The usage of acetone as a solvent may be 
responsible for this qualitative observation.  It is assumed that the decomposition 
pathway for 4-ASA includes the “decarboxylation of the active ingredient with the 
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formation of carbon dioxide” (Verreck, 2005).  This decarboxylation is generally caused 
by heat, but perhaps the electronegative oxygen of acetone triggers the drug’s 
decomposition.   
 
Figure 8:  Photo of Effect of Temperature on Appearance of Composite at 1500psi 
As observed in Figure 8, this phenomenon of discoloration was also observed in 
the high-pressure mixing products.  It seemed likely that the darkened color is due to 
degradation of the drug.  To reinforce this conclusion, a sample was processed using pure 
Eudragit at 120oC and 1500psi.  The color of the product is comparable to the samples 
formulated at the 80oC and 1500psi.  Figure 9 confirms the prior suspicion that the 




Figure 9: Comparison of Composite and Pure Polymer Processed in Mixer (120C, 1500 psi) 
 The discoloration was also observed when the pressure was increased from 1500 
to 2000 psi.  Whereas the composite processed at 80oC and 1500 psi looked much like 
pure Eudragit, the sample processed at 80oC and 2000 psi appears darker and more brittle 
(see Figure 10).  It was therefore decided to add a carbon dioxide purging step, prior to 
heating, to minimize the drug degradation.  In Figure 10, two samples are displayed for 
the 100oC, 2000 psi process conditions.  The sample on the left was heated before the 





Figure 10:  Composites Produced at Various Operating Conditions 
Figure 11 depicts the effect of purging with carbon dioxide before heating more 
clearly.  The product with the purging step appears very similar to the product of 80oC 
and 1500 psi, indicating minimum drug degradation.   
 
Figure 11:  Composites produced with and without CO2 purge 
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3.2  Differential Scanning Calorimetry Results 
A summary of the DSC results is found in Table 1.  Although, the OSM sample 
appears discolored, its drug enthalpy value is close to that of the pure drug and the 
composite processed at 80oC and 1500psi, indicating minimal degradation for both the 
OSM and the low parameter HPM samples.  It is observed that the melting peak for the 
composite samples is approximately 20oC higher than for the pure drug.  This could be 
the result of strong drug polymer interactions, namely hydrogen bonding, making the 
bonds of the solid material more difficult to break.  It should be noted that the onset 
temperature for melting the composite is close to the pure drug melting temperature.  
Additionally, the byproducts of drug degradation, namely various aminophenols, have 
higher melting temperatures than the drug itself.  It should also be noted that the melting 
peak for the OSM samples is noisier than that of the HPM samples, possibly indicating 
residual solvent.  As the operating temperature for the HPM samples is increased, the 
drug enthalpy value is decreased, again confirming the suspicion of drug degradation.  At 
2000 psi, no melting peaks are observed for the drug.  This could indicate complete 
degradation, but because no other byproduct signals are observed in the plot, it may also 
indicate that the drug is dispersed in its amorphous form.  Only the HPM-100C-2000psi-
C samples were purged with carbon dioxide prior to heating.  
Table 1:  Summary of DSC Results 




Pure Compounds       
Pure 4-aminosalicylic acid (1) -- 134.93 289.20 
Pure Eudragit (1) 56.41 -- -- 
Pure Eudragit (2) 54.47 -- -- 
HPM-Eudragit-120C,1500psi (1) 56.24 -- -- 
HPM-Eudragit-120C,1500psi (2) 60.38 -- -- 
HPM-Eudragit-120C,1500psi (3) 60.06     
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Composites   -- -- 
OSM-1 (1) 49.55 155.10 173.10 
OSM-1 (2) 52.36 162.54 175.70 
OSM-2 (1) 52.73 164.39 192.20 
OSM-2 (2) 52.77 163.51 200.00 
HPM-80C,1500psi (1) 55.04 152.57 181.70 
HPM-80C,1500psi (2) 56.15 155.04 194.80 
HPM-100C,1500psi (1) 43.87 152.23 63.53 
HPM-100C,1500psi (2) 41.82 155.19 47.06 
HPM-120C,1500psi (1) 44.70 150.75 43.35 
HPM-120C,1500psi (2) 45.89 151.34 42.52 
HPM-80C,2000psi (1) 52.97 -- -- 
HPM-80C,2000psi (2) 52.79 -- -- 
HPM-100C-2000psi-A (1) 48.41 -- -- 
HPM-100C-2000psi-A (2) 48.16 -- -- 
HPM-100C-2000psi-B (1) 52.09 -- -- 
HPM-100C-2000psi-B (2) 51.07 -- -- 
HPM-100C-2000psi-C (1) 55.44 -- -- 
HPM-100C-2000psi-C (2) 52.15 -- -- 
HPM-100C-2000psi-C (3) 55.25 -- -- 
HPM-100C-2000psi-C (4) 56.76 -- -- 
  
 In Table 1, it is observed that the Tg of the pelletized Eudragit is similar to the Tg 
of HPM processed Eudragit, indicating that after the carbon dioxide is released, it no 
longer serves as a plasticizer.  Figure 12 graphically depicts the glass transition 
temperatures of the HPM samples as a function of process temperature.  It is observed 
that the Tg of pure Eudragit is higher than the Tg of composite samples confirming the 
plasticization effect of the drug 4-ASA.   
The composite Tg generally decreases as the process temperature is increased.  At 
increased processing temperatures, viscosity is lowered, allowing for increased polymer 
chain mobility and better dispersion of drug.  The higher the quality of drug dispersion, 
the more effectively the drug can act as a plasticizer.  Drug degradation may have 
something to do with the slight increase in Tg from 100oC to 120oC.  Perhaps at 120oC, 
the degraded drug compound is not as effective of a plasticizer.   
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At 80oC, as pressure is increased from 1500 to 2000 psi, the Tg is lowered.  
Perhaps this can best be explained by the Free Volume Theory.  As the carbon dioxide 
pressure is increased, more fluid dissolves in the polymer melt, which increases the space 
between molecules.  Even after the pressure is released, this increased free volume 
reduces polymer chain interaction and therefore reduces Tg.  However, at 100oC, the 
opposite phenomenon is observed.  The Tg increases as processing pressure increases.  
Additionally, after the carbon dioxide purging step is included in this process, the Tg 
increases further, reaching values near that of the pure polymer.  This phenomenon is 
difficult to explain, but it should be noted that the drug is in its amorphous form at 2000 
psi.  The hydroxyl group on 4-ASA can serve as a hydrogen bond donor, while the 
double bonded oxygen in Eudragit can serve as a hydrogen bond acceptor.  As an 
amorphous dispersion is achieved, perhaps hydrogen-bonding between the drug and 
polymer can be used to explain this trend.    
 





































Figure 12:  Tg vs. Process Temperature for HPM samples 
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High-pressure DSC scans were attempted for the amorphous drug-polymer 
dispersions formed at 100oC and 2000psi.  However, because the starting temperature of 
these analyses was 25oC, and the baseline was very noisy at this temperature range, it was 
difficult to interpret any features of the plot.  It should be noted that no Tg transition was 
observed in the normal polymer range under pressurized CO2 (200-250psi). It may be 
assumed that the polymer Tg is depressed beyond its atmospheric range, but in order to 
gain any quantitative results, a cooling apparatus must be used in conjunction with the 
high pressure DSC to stabilize the baseline and allow a lower starting temperature. 
 
3.3  Fourier Transform Infrared Spectroscopy Results 
 Each composite sample, as well as the pure drug and polymer, were analyzed 
using FTIR spectroscopy.  Because the absorbance values of the spectra are dictated by 
sample concentration, ideally each sample should have been made at identical 
concentrations.  However, due to the accuracy of the scale in use, this was a difficult task.  
Figure 13 depicts the resulting IR spectra of the pure polymer, an organic solvent 
composite, and a high pressure mixer formulation (which was purged with CO2 prior to 


























Figure 13:  FTIR spectra of various samples 
Although it is difficult to interpret the spectra at this scale due to variance in 
absorbance values, no distinctions can be made between the OSM and the HPM sample.  
In fact, only 4 features distinguish the 10 wt% composite from pure Eudragit.  They 
consist of the following:  (1) a doublet from 3200-3400 cm-1, indicating the presence of a 
primary amine, (2) a carbon-carbon double bond stretch near 1500 cm-1, (3) C-O-H in-
plane bending around 1430 cm-1, and (4) a C-O-H out of plane bending around 930 cm-1. 
The remainder of drug features, as well as any drug-polymer interaction, remains 
hidden in the strong Eudragit signal.  No difference is observed for the drug in its 
amorphous state, and no drug degradation is evident from the IR spectra alone.  In order 
for the FTIR technique to be an effective analysis method in determining drug 
degradation and drug-polymer interaction, a higher concentration of drug must be used. 
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IV.  CONCLUSIONS 
A method for producing pharmaceutical/polymer composites using a supercritical 
carbon dioxide-assisted high-pressure mixing process has been investigated.  This batch 
operation has helped to determine the suitability of model materials for extrusion 
processes, while conserving costly pharmaceutical compounds.  Porous foams were 
created using the high-pressure mixing process.  Qualitatively, the advantages of the 
downstream processing of these foams relative to the organic solvent method products 
are obvious.  Milling and grinding of the foam product greatly reduces thermal and 
mechanical stresses on the composite, thus minimizing product degradation during 
downstream processing. 
Additionally, the plasticization effect of 4-aminosalicylic acid on Eudragit E100 
has been confirmed.  The glass transition temperature depression has been measured 
using differential scanning calorimetry.  At 2000 psi, amorphous drug dispersions have 
been formed via the high-pressure mixing method, without any residual solvent.  DSC 
results confirm that the drug is present in its crystalline form in the organic solvent 
method composites.  Furthermore, a noisy drug melting peak indicates that residual 
solvent may be present in the organic solvent method processes.  Amorphous drug 
dispersions should result in enhanced dissolution properties, and this increased 
dissolution rate represents another advantage of the foam product relative to the organic 
solvent method composite.  However, the extended residence time in the high-pressure 
mixer results in significant drug degradation at lower temperatures than previous research 
has indicated for extrusion processes.  Nevertheless, supercritical carbon dioxide-assisted 
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extrusion seems to be a promising technique for the processing of thermally-labile drug 
compounds in biodegradable polymers with low glass transition temperatures. 
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V.  RECOMMENDATIONS 
5.1  Experimental Considerations 
For the organic solvent method composites, residual solvent remains a concern.  
Because the vacuum oven did not sufficiently remove the employed solvent, additional 
measures should be utilized.  Perhaps a gas-solid fluidization column can be used to 
minimize residual solvent, by increasing the surface area of the product exposed to 
evaporation operations. 
The advantages of purging the high-pressure mixer system with carbon dioxide 
prior to heating have been confirmed.  This purging step helps to minimize drug 
degradation for the thermally-labile drug compound by preventing oxidation during the 
heating step.  The effect of residence time in the mixer on composition properties should 
also be investigated, to more accurately simulate extrusion. 
Additional analysis techniques should be employed to further confirm the 
conclusions drawn from this research.  Composites should be made at increased drug 
concentrations, so that Fourier-transform infrared spectroscopy analyses can be used to 
examine drug-polymer interactions.  Furthermore, high-pressure liquid chromatography 
techniques should be employed to quantitatively determine drug degradation, and 
examine the byproduct formation resulting from drug degradation. 
  
5.2  Recommendations for Extrusion 
High-pressure differential scanning calorimetry analyses should be conducted on 
the experimental materials.  Because of the low glass transition temperature of Eudragit 
E100, a cooling vessel should be attached to the HPDSC vessel for accuracy.  By 
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determining the effect of high-pressure carbon dioxide on the glass transition temperature 
depression of the composite, minimal operating temperature for extrusion can be 
quantified.  The extruder should then be operated at these temperatures to minimize 
degradation of the thermally-labile compound.  Adequate control of residence time in the 
extruder should be confirmed, to ensure a consistent product and further control 
degradation.   
Because the experimental materials were each susceptible to oxidation, the drug 
should be kept in a desiccator and purged with an inert gas before processing.  
Furthermore, an Aldrich® Atmosbag may be employed to minimize the atmospheric 
effects on the polymer prior to extrusion. 
Separate powder and pellet feeders should be calibrated and used to feed the 
experimental materials into the hopper of the extruder.  This feeding technique should 
result in a more consistent product composition than the product resulting from hand-
mixing the drug and polymer prior to input into the hopper.  If possible, the thermally-
labile drug compound should be injected into the extruder after the addition of carbon 
dioxide to the polymeric carrier, to minimize the processing temperatures of the drug.  
Perhaps a tandem extrusion setup could be employed.  
The composites resulting from extrusion should be compared to those produced 
by the high-pressure mixing method, to confirm the accuracy of the batch technique in 
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